Neurodegenerative Diseases

Neurodegenerative diseases are conditions in which nerve cells, or neurons, progressively sicken and die.

8 frameworks, from 1890 to today · Neurology · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Neurodegenerative diseases are conditions in which nerve cells, or neurons, progressively sicken and die1. The category includes Alzheimer's disease, the commonest cause of dementia; Parkinson's disease, a disorder of movement and much else; amyotrophic lateral sclerosis (ALS), which destroys the motor neurons that command muscles; Huntington's disease, an inherited disorder of movement, mood, and cognition; and a family of rarer conditions12. What unites them is a pattern: onset is usually gradual, decline is relentless, and the damage is selective—particular populations of neurons fail while their neighbours survive. The central questions of the field have been what makes those particular cells die, whether the process can be detected before symptoms appear, and whether it can be slowed or stopped. For most of the field's history the answer to the last question was no; the story of the last half-century is the slow, partial, and still unfinished attempt to change that.

The Clinicopathological Method and the First Named Diseases

Before the late nineteenth century, severe mental decline in old age was generally regarded as inevitable—senility rather than disease. The tools that changed this were the microscope and the systematic correlation of symptoms observed in life with tissue changes found after death, an approach neurologists call clinicopathological correlation. Its founding figure in this field was Alois Alzheimer, a German psychiatrist and neuropathologist. In 1906 he examined the brain of Auguste Deter, a woman in her fifties who had died after years of memory loss, disorientation, and hallucinations. He described two features: dense deposits between neurons, which came to be called amyloid plaques, and tangled bundles of fibres inside neurons, the neurofibrillary tangles. The condition was named Alzheimer's disease by Emil Kraepelin in 19102. The crucial move was conceptual: a clinical syndrome (dementia) had been matched to a specific tissue pathology, making it a disease with a definable lesion.

A parallel story produced Parkinson's disease. James Parkinson, a London physician, described "the shaking palsy" in 1817—resting tremor, stooped posture, slowed movement3. In 1912, Friedrich Lewy identified the characteristic round inclusions inside surviving neurons of the brainstem, now called Lewy bodies. In 1919 Konstantin Tretiakoff linked the disease specifically to loss of pigmented neurons in a midbrain structure, the substantia nigra ("black substance"), whose dark pigment is lost as its dopamine-producing cells die. ALS was described by Jean-Martin Charcot in the 1860s and 1870s, who showed degeneration of both the upper motor neurons in the cortex and the lower motor neurons in the spinal cord—a double lesion that explained the combination of weakness, wasting, and exaggerated reflexes14. Huntington's disease was named for George Huntington, who in 1872 gave a precise clinical and hereditary description of the chorea (involuntary dance-like movements) and its dominant pattern of inheritance5.

By the early twentieth century, then, the field had its core diseases, each defined by a characteristic lesion and a characteristic clinical course. What it lacked was any understanding of cause.

Neurochemistry and the First Replacement Therapy

The next turning point came from pharmacology. In the 1950s, Arvid Carlsson and colleagues showed that dopamine was a neurotransmitter in the brain, not merely a precursor of other molecules, and that animals depleted of dopamine became immobile—a state reversed by giving levodopa (L-dopa), the precursor the brain converts into dopamine67. In 1960, Oleh Hornykiewicz and colleagues found that the brains of Parkinson's patients were severely depleted of dopamine, concentrated in the striatum, the region the substantia nigra projects to. The logic was irresistible: if the disease is a chemical deficiency, replace the chemical. In 1961 Hornykiewicz and Walther Birkmayer gave L-dopa intravenously to Parkinson's patients and saw dramatic, if temporary, relief of rigidity and immobility7. By the late 1960s, oral high-dose L-dopa—championed by George Cotzias—was transforming the lives of patients who had been frozen and helpless7.

This was the founding success of neurotransmitter replacement in neurology, and it set a template: identify the missing transmitter, supply its precursor, and expect benefit. It also taught a sobering lesson. L-dopa worked, but after several years most patients developed fluctuations in response and involuntary movements (dyskinesias), and the drug did nothing for the underlying loss of neurons. Symptomatic relief was not disease modification. The same template was tried elsewhere—cholinergic drugs for Alzheimer's, for instance—with far more modest results, and the field learned that replacing a transmitter treats the symptom, not the disease.

Genetics: From Families to Molecules

The third turning point was genetic. Huntington's disease, with its clear dominant inheritance, was the test case. In 1983 a large collaborative effort led by James Gusella mapped the Huntington's disease gene to the short arm of chromosome 4; in 1993 the Huntington's Disease Collaborative Research Group identified the mutation—an expanded repeat of the trinucleotide sequence CAG within a gene now called HTT. The mechanism, a polyglutamine expansion, showed that a single inherited error could produce a slowly progressive, selective neurodegeneration1. It also introduced a new idea: the mutation is present from conception, yet disease begins decades later, so something about aging or cumulative damage must be involved.

Familial Alzheimer's disease yielded a different set of clues. In the early 1990s, mutations in the gene for amyloid precursor protein (APP) and in the presenilin genes (PSEN1, PSEN2) were found to cause rare, early-onset, dominantly inherited Alzheimer's. Crucially, all of these mutations increased production of a particular fragment of APP, the 42-amino-acid form of amyloid beta (Aβ42), the main constituent of plaques. In 1993, the ε4 variant of the apolipoprotein E gene (APOE) was reported by Allen Roses and colleagues as a major risk factor for the common, late-onset form of the disease. For Parkinson's disease, the first gene, alpha-synuclein (SNCA), was linked to rare familial cases in 1997; alpha-synuclein turned out to be the principal protein of Lewy bodies. In ALS, mutations in the gene for superoxide dismutase 1 (SOD1) were found in 1993 in a subset of familial cases1. Each discovery tied a disease to a specific protein, and the proteins converged on the pathology the microscopists had seen a century earlier.

The Amyloid Cascade and the Proteinopathy Framework

These genetic findings crystallized into the amyloid cascade hypothesis, articulated influentially by John Hardy and Gerald Higgins in 1992. The claim was that accumulation of amyloid beta is the initiating event in Alzheimer's disease, and that plaques set off a downstream chain—tangle formation, inflammation, synaptic loss, neuron death—that produces dementia. The hypothesis was compelling because it explained the genetics: every known causative mutation pushed amyloid production up. It made a bold prediction: remove amyloid, and the disease should halt.

The broader framework that emerged is proteinopathy: the idea that many neurodegenerative diseases are defined by the misfolding and aggregation of a particular protein8. Alzheimer's has amyloid and tau (the protein of tangles); Parkinson's and dementia with Lewy bodies have alpha-synuclein; ALS and frontotemporal dementia have TDP-43 in most cases; Huntington's has mutant huntingtin; prion diseases have the prion protein. The framework gave the field a common language and a common target—misfolded protein—across diseases that had seemed unrelated.

Prions and the Idea of Propagation

A strange observation forced a revision. Prion diseases—Creutzfeldt-Jakob disease in humans, scrapie in sheep, bovine spongiform encephalopathy in cattle—were transmissible, yet no virus or bacterium could be found. Stanley Prusiner proposed in 1982 that the infectious agent was a protein, a "prion," and that it spread by converting normal protein into the misfolded form. The idea was initially met with scepticism but was vindicated; Prusiner received the Nobel Prize in 1997. The deeper implication, developed from the 2000s onward, was prion-like propagation: misfolded proteins can seed the misfolding of their normal counterparts and spread from cell to cell along anatomical pathways. This reframed Alzheimer's, Parkinson's, and ALS not as static accumulations but as spreading processes—which helped explain why pathology appears in predictable anatomical stages, as described for Alzheimer's by Heiko and Eva Braak, and for Parkinson's by Braak and colleagues.

Biomarkers and the Move to Preclinical Disease

If disease begins years or decades before symptoms, then diagnosis at the symptomatic stage is late. This drove the development of biomarkers—measurable indicators of disease. In Alzheimer's, the key advances were the ability to measure amyloid beta and tau in cerebrospinal fluid (low Aβ42, high tau reflecting plaque and tangle burden) and, from the early 2000s, amyloid PET imaging, which allowed plaques to be seen in a living brain. These tools revealed that a substantial fraction of cognitively normal older people already carry Alzheimer's pathology. The field responded by redefining the disease: in the 2010s, research frameworks proposed that Alzheimer's be defined biologically by its pathology rather than by dementia, creating a category of preclinical Alzheimer's disease. Similar staging efforts followed for Parkinson's, where imaging of dopamine terminals and, later, alpha-synuclein seed amplification assays in spinal fluid offered ways to detect the process early.

The Long Campaign for Disease-Modifying Therapy

The amyloid cascade made a clear therapeutic bet, and the field spent a quarter-century testing it. Early anti-amyloid vaccines and antibodies failed in large trials—some, like the AN1792 vaccine trial, caused serious brain inflammation, and others showed no cognitive benefit. A widely discussed 2006 paper in Nature by Sylvain Lesné and colleagues, which reported that a specific soluble amyloid oligomer caused memory deficits in rats, was later found to contain manipulated images and was retracted in 2024; the episode shook confidence but did not overturn the broader hypothesis. The turning point came with antibodies that reliably cleared plaques. In 2021 the FDA granted accelerated approval to aducanumab amid controversy over its marginal clinical benefit; in 2023 lecanemab was reported to slow cognitive decline modestly in early Alzheimer's, and donanemab followed. These were the first treatments shown to alter the course of the disease rather than only its symptoms—small effects, real side effects (brain swelling and bleeding), and a genuine proof of principle that the amyloid pathway is causally relevant.

For Parkinson's, disease-modifying attempts have been less successful; trials of dopamine-cell transplantation and of various neuroprotective agents have not delivered. For ALS, riluzole (approved 1995) and edaravone offer modest survival or functional benefit, and antisense therapies targeting SOD1 represent a genetically targeted approach for a small subset. For Huntington's, antisense oligonucleotide trials aimed at lowering mutant huntingtin have been pursued, with results still unfolding.

Where the Field Stands

Today the main approaches descend directly from this history. Clinicopathological correlation remains the bedrock, now extended by biomarkers that let the pathology be inferred in life. Proteinopathy and the prion-like propagation idea organize research across diseases, and the search for therapies targets the aggregation, spread, and clearance of specific proteins. Genetics has moved from rare families to large-scale studies identifying dozens of risk variants, and antisense oligonucleotides and gene-based strategies offer ways to lower toxic proteins at their source. Biomarker-based and preclinical staging is reshaping how trials are designed—treating people before symptoms, when neurons can still be saved.

The open questions are the ones the history has exposed. Why are particular neurons vulnerable? What triggers the process in the first place? Why do some people with abundant pathology remain cognitively normal? And can the modest slowing achieved with anti-amyloid antibodies be turned into something that meaningfully changes the course of disease—and extended to the other neurodegenerative conditions, where the therapeutic ledger is still largely blank.

References

  1. Neurodegenerative disease (introduction, Amyotrophic lateral sclerosis, Huntington's disease, Genetics), Wikipedia
  2. Alzheimer's disease (introduction, History), Wikipedia
  3. Parkinson's disease (History), Wikipedia
  4. ALS (History), Wikipedia
  5. Huntington's disease (History), Wikipedia
  6. Dopamine (History and development), Wikipedia
  7. Levodopa (History), Wikipedia
  8. Proteinopathy, Wikipedia

The frameworks of Neurodegenerative Diseases

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1890-Present

    Clinicopathological Correlation

    Which tissue changes explain a patient's symptoms?

    Fly to its tower in Nousfarer

  2. 1960-Present

    Neurotransmitter Replacement

    Can replacing a missing chemical relieve symptoms?

    Fly to its tower in Nousfarer

  3. 1982-Present

    Prion-like Propagation

    Can misfolded proteins spread from cell to cell?

    Fly to its tower in Nousfarer

  4. 1983-Present

    Neurogenetics

    Which genes cause inherited neurodegeneration?

    Fly to its tower in Nousfarer

  5. 1990-Present

    Disease-modifying treatment

    Can the course of the disease be slowed?

    Fly to its tower in Nousfarer

  6. 1990-Present

    Proteinopathy

    Which misfolded protein defines each disease?

    Fly to its tower in Nousfarer

  7. 1992-Present

    Amyloid Cascade Hypothesis

    Does amyloid accumulation initiate Alzheimer's disease?

    Fly to its tower in Nousfarer

  8. 2000-Present

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Clinicopathological CorrelationNeurotransmitter ReplacementPrion-like PropagationNeurogeneticsDisease-modifying treatmentProteinopathyAmyloid Cascade HypothesisBiomarker-Based Staging and Preclinic…

Beyond the field

Where Neurodegenerative Diseases's ideas came from in other fields, and what they led to there: the strongest 12 of 31 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Neurodegenerative Diseases is a planet in Nousfarer

Its city has a tower for each of these 8 frameworks. Land, walk in, and climb one concept at a time.

Land on Neurodegenerative Diseases

Related fields

Fields its ideas are linked to

More in Neurology

See where Neurodegenerative Diseases sits on the Map of Human Knowledge